Short answer
Arcutis Biotherapeutics, Inc. (ARQT) filed an 8-K current report with the SEC on February 25, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 2025 earnings press release issued Feb 25, 2026: full results in Exhibit 99.1.
Arcutis Biotherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings press release issued Feb 25, 2026: full results in Exhibit 99.1
- Dermatology-focused biopharma; revenue trajectory and path to profitability key investor focus given commercial-stage products (ZORYVE line)
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Arcutis Biotherapeutics, Inc. 8-K filings
Get the next ARQT 8-K as it lands
Follow ARQT for push alerts, or ask the research agent what this filing means.